NCT06066710 · Early Phase 1 · RECRUITING
Propranolol in Primary Progressive Aphasia
This small study looks at how propranolol, a blood pressure drug already used for heart conditions, affects language in people with Primary Progressive Aphasia, a condition that gradually erodes speech and language. Researchers compare it with a placebo and use brain MRI scans. It is an early Phase 1 trial, meaning a first look, not proof it works.
You may qualify if
- 1. Age: 50 and older
- 2. Primary Progressive Aphasia diagnosis
- 3. Native English speaker
You're excluded if
- 1. Unable to provide consent
- 2. Taking alpha 2 agonists (clonidine and guanfacine)
- 3. Other major psychological or neurological diagnosis
- 4. Major head trauma that contributed to their condition
- 5. Allergic reaction to adhesives
- 6. Uncorrected vision/hearing impairments
- 7. Diabetes
- 8. Reactive airway disease
- 9. Untreated hypothyroidism
- 10. Bradyarrhythmia
- 11. Unexplained syncope
- 12. Pregnancy (assessed verbally on the days of MR imaging)
- 13. Drugs that interact with propranolol, such as alpha 2 agonists
- 14. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-17